Shanghai Pharma to send H 8 billion

If Shanghai medicine successfully landed in H-shares, it would become the third A+h large listed company following Shanghai Electric and Pacific Insurance. Yesterday, the Shanghai Medical Bulletin said that the company intends to open the IPO to foreign investors not more than the diluted shares of 25% of the total share capital, is expected to raise funds not less than 8 billion yuan, mainly for domestic and overseas pharmaceutical industry projects, mergers and acquisitions, pharmaceutical business network construction and mergers and acquisitions and other areas of investment　　Shanghai Medical Board yesterday Rose 5% and received 19.23 yuan. Yesterday, the reporter learned from the Shanghai Medical Group that the announcement of the company's motion on the issuance of H shares and listing in Hong Kong had been considered by the company's board of directors.　　Shanghai medical sources said that the Shanghai Pharmaceutical H-shares issued by the Hong Kong public offering and international placements, the issue of time to be determined, the issue price will not be less than the first 20 trading day of the average price of 90%, that is, the prices per share will not be less than 18 yuan. According to the introduction, in the pharmaceutical industry, Shanghai Medicine intends to achieve the expansion of existing products and product lines through the acquisition of pharmaceutical group antibiotic business and related assets, as well as the strategic pharmaceutical industry quality assets of other non pharmacy groups. In the pharmaceutical business, the company intends to adopt strategic-oriented external mergers and acquisitions in the Bohai Rim,　　Establishment of regional operations centers in East and South China; In addition, the company is committed to upgrading the market share of the market in the mainstream hospitals, and to the Regional Operations center to cover the depth of the community, rural and other high-growth third terminal market. Yesterday, the reporter learned that the group is currently operating in China Health group's assets to Hong Kong listed projects, if the row, it will have the Chinese after the other listed subsidiary in Hong Kong.